



University of Southern Denmark

**The Effect of Virtual Reality on Cold Pain Sensitivity in Patients with Fibromyalgia and Pain-Free Individuals  
A Randomized Crossover Study**

Christensen, Steffan Witttrup McPhee; Almsborg M, Heidi; Vain M, Thomas Søggaard; Vaegter, Henrik Bjarke

*Published in:*  
Games for Health

*DOI:*  
10.1089/g4h.2022.0138

*Publication date:*  
2023

*Document version:*  
Accepted manuscript

*Document license:*  
CC BY

*Citation for polished version (APA):*

Christensen, S. W. M., Almsborg M, H., Vain M, T. S., & Vaegter, H. B. (2023). The Effect of Virtual Reality on Cold Pain Sensitivity in Patients with Fibromyalgia and Pain-Free Individuals: A Randomized Crossover Study. *Games for Health*, 12(4), 295-301. <https://doi.org/10.1089/g4h.2022.0138>

Go to publication entry in University of Southern Denmark's Research Portal

**Terms of use**

This work is brought to you by the University of Southern Denmark.  
Unless otherwise specified it has been shared according to the terms for self-archiving.  
If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim.  
Please direct all enquiries to [puresupport@bib.sdu.dk](mailto:puresupport@bib.sdu.dk)

**THE EFFECT OF VIRTUAL REALITY ON COLD PAIN SENSITIVITY IN PATIENTS WITH FIBROMYALGIA  
AND PAIN-FREE INDIVIDUALS - A RANDOMIZED CROSS-OVER STUDY**

Steffan Wittrup McPhee Christensen<sup>1,2</sup>, Heidi Almsborg<sup>1,3</sup>, Thomas Sjøgaard Vain<sup>1,4</sup>,  
Henrik Bjarke Vaegter<sup>5,6</sup>

<sup>1</sup>Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.

<sup>2</sup>Department of Physiotherapy, University College of Northern Denmark, Aalborg, Denmark.

<sup>3</sup>Multidisciplinary Pain Center Naestved, Naestved Hospital, Naestved, Denmark.

<sup>4</sup>Smertefys.nu, Physiotherapy Clinic, Copenhagen, Denmark.

<sup>5</sup>Pain Research Group, Pain Center, Department of Anesthesiology and Intensive Care Medicine, Odense University Hospital, Odense, Denmark.

<sup>6</sup>Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

**Original article** for Games for Health Journal

**Running head:** VR modulates pain in Fibromyalgia

**Keywords:** Fibromyalgia, Virtual Reality, pain tolerance, pain threshold, pain intensity, pain catastrophizing.

**Corresponding Author:**

Associate Professor Steffan Wittrup McPhee Christensen.

Department of Health Science and Technology, Aalborg University.

Fredrik Bajers Vej 7D-3, Aalborg, Denmark.

9220 Aalborg E, Denmark.

Phone: +45 99408889

E-mail: stc@hst.aau.dk

## 1 INTRODUCTION

2 Fibromyalgia is a challenging condition to manage in clinical practice.<sup>1-3</sup> So far, no superior treatment  
3 strategy exists and a multimodal approach is recommended.<sup>4,5</sup> Although the underlying mechanism  
4 of fibromyalgia remains an enigma, it has been suggested that altered central processing of  
5 nociceptive input may be a contributing factor.<sup>1,6</sup> While studies have found increased pain sensitivity  
6 in those with fibromyalgia compared with a pain-free population, the magnitude may be related to  
7 the levels of catastrophizing.<sup>7-10</sup> Furthermore, levels of pain catastrophizing may mediate pain  
8 intensity during physical activity in fibromyalgia.<sup>11</sup>

9           Distraction, defined as the ability to move focus away from pain<sup>12,13</sup>, has been shown  
10 to reduce pain intensity, increase pain threshold and -tolerance in pain-free individuals.<sup>14,15</sup>  
11 However, in chronic pain patients, distraction did not have a consistent hypoalgesic effect<sup>16</sup> which  
12 could be related to attentional bias to pain and pain related cognitions like pain catastrophizing.<sup>17,18</sup>  
13 In fact, high levels of catastrophizing may lead to an impaired ability to be distracted from pain.<sup>10,19</sup>

14           A treatment modality used to create an interactive distraction from pain is Virtual  
15 Reality (VR), which allows for moving and solving tasks in a predesigned environment. Studies have  
16 shown VR being capable of reducing pain intensity, increase pain threshold and -tolerance for the  
17 user with the suggested explanation being distraction from noxious input.<sup>20</sup> One study found  
18 reduced pain intensity following exercise training with and without VR in fibromyalgia patients, with  
19 the largest effect seen for those using VR.<sup>21</sup> However, the previous study did not investigate the  
20 immediate effect of VR on pain intensity, -threshold and -tolerance. Knowledge on how VR may  
21 modulate pain in fibromyalgia patients is of great interest if this is to be recommended as part of a  
22 pain modulatory treatment strategy, alone or in combination with other modalities.

23           The primary aim of this study was to investigate the effect of VR on pain threshold, -  
24 tolerance and -intensity during ice water immersion compared with ice water immersion without  
25 VR in fibromyalgia patients and in pain-free individuals. It was hypothesized that VR would reduce  
26 pain intensity, increase pain threshold and -tolerance in both fibromyalgia patients and pain-free  
27 individuals. A secondary aim was to explore if higher pain catastrophizing was associated with  
28 smaller effects of VR.

29

## 30 MATERIALS AND METHODS

1 The Consolidated Standards of Reporting Trials of Non-pharmacological Treatments (CONSORT NPT)  
2 were used as a guideline for reporting this study.<sup>22</sup> The trial was preregistered at ClinicalTrials.gov  
3 (NCT04294914), approved by the Danish Data Protection Agency (REG-004-2020) and the local  
4 ethics committee (SJ-822). All participants provided written informed consent before commencing  
5 the study. The study was conducted at the Multidisciplinary Pain Center in Næstved, Denmark from  
6 February 2020 to May 2020.

7

### 8 *Design*

9 A within-subject randomized cross-over design (VR and control condition) for the fibromyalgia group  
10 and pain-free individuals, respectively was used in this non-blinded study. All participants  
11 participated in one session with two conditions lasting in total approximately 50-minutes. The order  
12 of the conditions was randomized and counterbalanced for patients with fibromyalgia and pain-free  
13 controls. Between conditions there was a 20-minutes break (Fig. 1). Prior to enrolling in the study,  
14 all participants had a 3-minute familiarization session to ensure they tolerated the VR experience.

15

### 16 *Participants*

17 Twenty-two female fibromyalgia patients with a mean age of 47.6 years (SD 6.6) were recruited  
18 from the Multidisciplinary Pain Center in Næstved, Denmark, along with 22 sex- and age matched  
19 pain-free individuals recruited via Facebook adverts seeking healthy participants for a research  
20 study. The inclusion criteria for all participants were women 18-65 years old, being able to read,  
21 speak and understand Danish. Participants for both groups were excluded if they were receiving  
22 treatment for anxiety, depression or post-traumatic stress disorder. Additionally, any potential  
23 malignant diseases, pregnancy or conditions impacting on normal sensation in the feet were also  
24 cause for exclusion. Fibromyalgia patients had to be diagnosed according to the Criteria for  
25 Classification of Fibromyalgia by a rheumatologist<sup>23,24</sup> and were excluded if they have had any recent  
26 adjustment to their medication such as anticonvulsive, serotonin-norepinephrine reuptake inhibitor  
27 (SNRI) or Tricyclic antidepressant (TCA). Pain-free individuals were excluded if they experienced any  
28 recurrent or ongoing painful condition whereas slight headaches or any other normal types of  
29 unpleasantness commonly reported by the general population were allowed. However, in case of  
30 regular use of analgesic medication pain-free individuals were excluded.

1

## 2 *Randomization*

3 The randomization of test order, control or VR first, was generated in a balanced way so half of each  
4 group would start with the control condition before crossing over to the VR condition and vice versa.  
5 The randomization was stored in individual sealed opaque envelopes, and after inclusion,  
6 participants chose an envelope which determined their test order.

7

## 8 *Interventions*

9 For the control condition (CC), participants were seated in a comfortable position on a chair with a  
10 backrest. From this position they were asked to place their dominant foot into a tub containing ice  
11 water (1-2°C)<sup>25,26</sup> and keep it there until it was perceived as too painful at which timepoint  
12 participants could remove their foot. A maximal duration of the cold pressor test was set to three  
13 minutes (180-seconds)<sup>27</sup> although this was not communicated to any of the participants in order to  
14 reduce the risk of making the time limit a goal for the participants. The temperature was monitored  
15 using a digital thermometer (Vores, Naestved, Denmark) and kept consistent using ice cubes in a  
16 separated section of the tub with a pump (Eheim, Deizisau, Germany) ensuring continuous  
17 circulation. For the VR condition (VR-C), the cold pressor task was performed identically with the CC  
18 while the participant was exposed to a VR-environment. For the VR-C, an Oculus Rift S VR headset  
19 (v.5407469, Oculus, California, United States) with audio, three motion detectors and two hand-  
20 controllers were used. During the experiment, the VR-software simulated a birthday party. In this  
21 non-social immersive environment, participants (first-person perspective) were able to move  
22 around, see and use their hands to lighting candles or lift packages from the floor etc.

23

## 24 *Outcomes*

25 The primary outcomes were cold pain threshold, cold pain tolerance and pain intensity in the  
26 dominant foot. Secondary outcomes were scores on the pain catastrophizing scale and dizziness.  
27 Cold pain threshold, defined as the time (seconds) from the participants immersed their foot in the  
28 cold water until they started to feel the first sensation of pain<sup>28</sup> was recorded for each condition.  
29 Similarly, cold pain tolerance, defined as the time (seconds) from the participants immersed their  
30 foot in the water and until they removed their foot due to pain<sup>29</sup> was recorded. Pain intensity in the

1 dominant foot was assessed on a 10cm Visual Analog Scale (VAS) anchored with 0 as “no pain” and  
2 10 as “maximal imaginable pain”<sup>30,31</sup> immediately after each ice water condition (CC; VR-C).

3 As high levels of catastrophizing may impact the ability to be distracted from pain <sup>32</sup>  
4 and thereby the potential efficacy of VR on pain, all participants completed a Danish version of the  
5 Pain Catastrophizing Scale (PCS) questionnaire<sup>33</sup> at the beginning of the session. The PCS consists of  
6 thirteen questions which are answered using a 5-point Likert scale anchored with “Not at all” as 0  
7 and “Very much” as 4, giving a maximal score of fifty-two.<sup>34</sup> Higher scores indicate higher levels of  
8 pain catastrophizing.

9 Dizziness was assessed using a 10cm VAS<sup>35</sup> anchored with 0 as “no dizziness” and 10  
10 as “maximal imaginable dizziness” immediately before and after each cold pressor condition as this  
11 may be experienced by some participants when using VR.<sup>36,37</sup> Furthermore, participants were asked  
12 to provide information on their age and leggedness, while fibromyalgia patients provided the time  
13 since receiving their fibromyalgia diagnosis.

#### 14 *Statistics*

15 G\*power v3.1.9.4 (Heinrich-Heine-Universität, Düsseldorf, Germany), was used for a sample-size  
16 calculation for a paired t-test. A power of 80% and a two-sided significance level of 0.05 was used.  
17 Cohen's *d* of 0.64 was based on a previous study<sup>27</sup> investigating pain threshold during a cold pressor  
18 test with and without VR. Based on this, a sample size of 22 was needed for each group. Data-  
19 distribution was assessed using the Shapiro-Wilk test and the appropriate statistically analysis was  
20 conducted.

21  
22 *Main analyses:* To investigate the effect of VR in patients with fibromyalgia and pain-  
23 free individuals, cold pain threshold, -tolerance and -intensity were compared between the two  
24 conditions (CC and VR-C) using Wilcoxon's tests. Effect size was reported as Eta Squared ( $\eta^2$ ) and  
25 interpreted as large ( $\geq 0.14$ ), moderate (0.06) and small (0.01) using Cohen's criteria.<sup>38,39</sup>

26 *Exploratory analyses:* To explore the hypothesis that higher pain catastrophizing  
27 scores were associated with smaller effects of VR, Pearson's (*r*) or Spearman's (*r<sub>s</sub>*) correlation  
28 coefficient analysis (based on data distribution) between PCS scores and change in pain threshold,  
29 -tolerance and -intensity (scores in VR-C minus scores in CC) were conducted. Correlations

1 coefficients were categorized as large ( $\geq 0.50$ ), moderate (0.3) or small (0.1) effect sizes using  
2 Cohen's criteria.<sup>38,39</sup>

3 Finally, to examine if simulator sickness had occurred because of VR, change in  
4 dizziness scores over time (pre-test, post-test) for the CC and VR-C were compared using Wilcoxon's  
5 tests for each group (fibromyalgia, pain-free). All statistical analyses were conducted using SPSS v.27  
6 (IBM, Chicago, IL, USA) and P values of 0.05 or less were considered significant. Data are presented  
7 as median and interquartile range (25th and 75th percentile) unless stated otherwise.

8

## 9 **RESULTS**

10 A total of 22 fibromyalgia patients and 22 pain-free individuals underwent randomization (Table 1)  
11 and completed all conditions with no reported adverse events. Neither group reported any  
12 significant dizziness changes during CC (fibromyalgia: pre 0.60 [0.0-3.13] and post 0.55 [0.0-2.63],  
13  $P=0.89$ ,  $\eta^2<0.01$ ; Pain-free: pre 0.0 [0.0-0.05], and post 0.0 [0.0-1.0],  $P=0.58$ ,  $\eta^2=0.02$ ) or VR-C  
14 (fibromyalgia: pre 0.5 [0.0-2.6], and post 0.55 [0.0-3.38],  $P=0.17$ ,  $\eta^2=0.09$ ; Pain-free: pre 0.0 [0.0-  
15 0.05], and post 0.00 [0.0-0.08],  $P=0.13$ ,  $\eta^2<0.01$ ). For CC, 2 fibromyalgia patients (9.1%) tolerated  
16 the full 180-seconds of ice water immersion while this was the case for 12 pain-free participants  
17 (54.5%). During VR-C, 6 fibromyalgia patients (27.3%) and 20 pain-free participants (90.9%) endured  
18 the 180-seconds.

19

### 20 *Effect of VR on primary outcomes*

21 A large and significant increase in cold pain threshold was observed in the VR-C compared to the CC  
22 for both the fibromyalgia group ( $P<0.001$ ,  $\eta^2=0.63$ , Fig. 2a) and the pain-free group ( $P<0.001$ ,  $\eta^2=$   
23 0.66). Similarly, higher pain tolerance was found in the VR-C compared to CC for both the  
24 fibromyalgia group ( $P<0.001$ ,  $\eta^2=0.50$ , Fig. 2b) and the pain-free-group ( $P=0.028$ ,  $\eta^2=0.22$ ). The  
25 pain-free group displayed a significant reduction in pain intensity following the VR-C compared to  
26 the CC ( $P<0.003$ ,  $\eta^2=0.40$ , Fig. 2c), whereas the fibromyalgia did not ( $P=0.231$ ,  $\eta^2=0.07$ ). Mean  
27 difference, SD and 95% CI can be seen in supplementary file 1.

28

### 29 *Associations between pain catastrophizing and VR effects*

1 No significant correlations between pain catastrophizing scores and effect of VR on pain threshold  
2 (fibromyalgia:  $r_s(20)=-0.25$ ,  $P=0.27$ ; pain-free:  $r_s(20)=0.44$ ,  $P=0.85$ ), tolerance (fibromyalgia:  $r_s(20)=-$   
3  $0.35$ ,  $P=0.11$ ; pain-free:  $r_s(20)=0.40$ ,  $P=0.06$ ) or pain intensity (fibromyalgia:  $r_s(20)=0.22$ ,  $P=0.33$  and  
4 pain-free:  $r=-0.36$ ,  $n=22$ ,  $P=0.99$ ) were observed.

5

## 6 **DISCUSSION**

7 The main finding of this study was that VR had large and significant effects on cold pain thresholds  
8 and -tolerance in patients with fibromyalgia and moderate to large effects in pain-free individuals.  
9 A positive effect of VR on pain intensity was only observed in pain-free individuals. Taken together,  
10 the results indicate that VR may have a positive influence on the pain threshold and tolerance and  
11 future studies exploring the potentials for VR as part of pain management outside a laboratory  
12 setting is warranted.

13 A novel finding of the current study is that while pain-free individuals reported  
14 reduced pain intensity during VR-C compared to CC this was not seen for the fibromyalgia group.  
15 This lack of reduction for pain intensity in the fibromyalgia group is somewhat surprising as the  
16 existing literature suggest that using VR should lower pain intensity by distracting the user from pain  
17 which has recently been shown in both persistent painful conditions like chronic low back pain<sup>40</sup> as  
18 well as in experimental pain in healthy populations.<sup>27,41-44</sup> One explanation could be that even  
19 though distraction, in this study by using VR, can be used to divert from experimental pain<sup>20,45</sup> the  
20 fibromyalgia group may not have the same beneficial effect as the control group.<sup>46</sup> The reduced  
21 ability to be distracted could be impacted by the level of pain intensity experienced by the  
22 fibromyalgia group compared to the control group prior to the two conditions. The underlying  
23 mechanism here might then be a potential lack of attentional resources for other tasks, such as  
24 engaging with the VR experience, as pain itself draws on attentional resources and the level of  
25 perceived threat by pain may play an important role in this.<sup>47</sup> While some studies suggest that  
26 distraction from pain may not be impaired in patients with fibromyalgia compared to pain-free  
27 controls<sup>48,49</sup> there is also evidence suggesting the opposite. In contrast to the current findings of no  
28 correlation, one study indicated that not only is the ability to distract from pain, measured as  
29 reduced pain intensity in fibromyalgia patients compared to pain-free controls, impaired but it is  
30 also associated with pain catastrophizing.<sup>10</sup> It has been hypothesized that the difficulty to disengage



1 from pain through the use of VR can be driven by pain-related cognitions (e.g. pain catastrophizing<sup>50</sup>)  
2 that may have affected the VR induced hypoalgesia. This is supported by a previous study<sup>19</sup> where  
3 participants with high pain catastrophizing had reduced analgesic effect of distraction initially but  
4 not over time. While the current study did not show any significant impact of pain catastrophizing  
5 on neither pain threshold, -tolerance or -intensity, the current findings are in line with a recent study  
6 in individuals with chronic low back pain which found no moderating role of pain catastrophizing on  
7 the effect of VR on pain.<sup>40</sup>

8 Clinically, the aim of pain management for patients with fibromyalgia is to achieve  
9 their valued life goals, often through involvement in exercise programs. However, despite exercise  
10 training showing positive effect on pain over time<sup>51,52</sup> adherence to such programs may be limited  
11 due to increases in pain following exercise.<sup>53</sup> A recent study showed pain reduction over time  
12 following exercise training with VR which was larger than without VR although this was non-  
13 significant.<sup>21</sup> In addition, Polat et al.<sup>21</sup> found a significant increase in cardiovascular performance  
14 and reduced fatigue when compared exercise training without VR which they argued could be due  
15 to decreased perception of pain. This is supported by the current results where both pain threshold  
16 and -tolerance was increased although no immediate effect was seen for pain intensity in the  
17 fibromyalgia group. Taken together, our results show that VR can modulate pain and if used in  
18 combination with exercise as in the previous study<sup>21</sup>, this could make exercise more tolerable to a  
19 fibromyalgia population which in turn may increase adherence to exercise training. However, future  
20 prospective randomized controlled studies are needed to investigate the feasibility of using VR in  
21 both a clinical setting as well as for self-management in combination with exercise.

22

### 23 *Limitations*

24 There are several limitations that need consideration when interpreting the results of the current  
25 study. This study only included women and the results may not generalize to men.

26 The current results were based on experimental pain and the VR effect on clinical  
27 fibromyalgia pain remains unclear. Furthermore, this study did not consider the potential influence  
28 of where pain fibromyalgia patients perceived their pain.

29 A major limitation in the current study is the high number of participants who reached  
30 the cold pressor time-limit of 180-seconds which could potentially influence the true effect of VR

1 on pain tolerance and pain intensity. Due to the proportion of participants reaching the limit of 180-  
2 seconds strongly suggests that tolerance results should be interpreted with caution. This ceiling  
3 effect indicated that participants in both groups achieved an adaptation to the cold water even  
4 though actions were made to minimize this. The maximal limit of time in the cold water was set to  
5 180-seconds. Some studies have used a maximum limit of 5-minutes,<sup>27,54</sup> which could have caused  
6 less participants reaching the maximal tolerance time in the current study. Additionally, assessing  
7 pain threshold may have affected the distractive effect of VR as participants had to identify when  
8 they first experienced pain,<sup>55</sup> which could have been avoided by only recording tolerance values.  
9 However, as discussed above, the tolerance values have their own limitations. Furthermore, it is  
10 recommended to include both pain -tolerance and threshold as one assesses the ability to  
11 discriminate nociceptive input while the other represents the willingness to endure additional  
12 pain.<sup>56</sup>

13 In the current study there was no assessment of the level of immersion with VR or if  
14 this was related to the duration of ice water submersion nor was the amount of body movement  
15 tracked, both of which has the potential to influence the results and future studies should include  
16 these parameters. Another potential limitation is that the control condition did not employ a true  
17 control (e.g. inactive VR) and this could potentially have caused an overestimation of the VR effects.  
18 Furthermore, this study did not investigate the effect of VR on clinical pain; therefore, the results  
19 may have limited ecological validity and cannot be directly translated into treatment effects and  
20 future studies are needed to clarify this issue. The clinical transferability is further compromised by  
21 pain was only assessed immediately after the VR intervention, and not over a longer  
22 postintervention period which would be of clinical relevance. In addition, the participants were only  
23 women, and the current results may therefore no be directly transferable to male participants.  
24 Lastly, although the hypotheses were not reviled to the participants (e.g. VR was expect to increase  
25 the pain threshold and tolerance), it is possible that the lack of participant blinding to VR-C and CC  
26 might have influenced the results in case participants expected positive effects from VR.

27

## 28 **CONCLUSION**

29 VR had large positive effects on cold pain thresholds and pain tolerance in patients with fibromyalgia  
30 and pain-free individuals. For pain intensity a large positive effect of VR was seen for pain-free

1 individuals but not fibromyalgia patients. No association was shown between pain catastrophizing  
2 and the effects of VR on pain threshold, -tolerance or -intensity. Future prospective studies  
3 exploring the feasibility and immediate effect of VR as part of clinical pain management for people  
4 with fibromyalgia is warranted.

5

6 **Acknowledgements**

7 The authors would like to thank the Multidisciplinary Pain Center Naestved and Smertefys.nu for  
8 the use of equipment, providing access to facilities and for assisting with recruitment of patients for  
9 the study.

10

11 **Author Contributions**

12 HA, TSV, HBV & SWMC developed the idea and methods used for the current project. HA and TSV  
13 collected data. All authors contributed to the data-analysis and interpretation as well as preparing  
14 the manuscript.

15

16 **Conflict of Interest:** Steffan Wittrup McPhee Christensen has received support from the Fund for  
17 Research, Quality and Education in Physiotherapy Practice (Fysioterapipraksisfonden) and the  
18 Lundbeck Foundation for Health Care Research within the last 5 years. The funders did not have any  
19 role in this study. There are no actual or potential conflicts of interest for any of the other authors.

20

21 **Funding Sources:** No funding was obtained for this stud

## REFERENCES

1. Sluka KA, Clauw DJ. Neurobiology of fibromyalgia and chronic widespread pain. *Neuroscience* 2016;338:114-129; doi: 10.1016/j.neuroscience.2016.06.006.
2. Creed F. A review of the incidence and risk factors for fibromyalgia and chronic widespread pain in population-based studies. *Pain* 2020;161(6):1169-1176; doi: 10.1097/j.pain.0000000000001819.
3. Jones GT, Atzeni F, Beasley M, et al. The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. *Arthritis Rheumatol* 2015;67(2):568-575; doi: 10.1002/art.38905.
4. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. *Annals of the rheumatic diseases* 2017;76(2):318-328; doi: 10.1136/annrheumdis-2016-209724.
5. Aman MM, Jason Yong R, Kaye AD, et al. Evidence-Based Non-Pharmacological Therapies for Fibromyalgia. *Curr Pain Headache Rep* 2018;22(5):33; doi: 10.1007/s11916-018-0688-2.
6. Borchers AT, Gershwin ME. Fibromyalgia: A Critical and Comprehensive Review. *Clin Rev Allergy Immunol* 2015;49(2):100-151; doi: 10.1007/s12016-015-8509-4.
7. Stevens A, Batra A, Kotter I, et al. Both pain and EEG response to cold pressor stimulation occurs faster in fibromyalgia patients than in control subjects. *Psychiatry Res* 2000;97(2-3):237-247; doi: 10.1016/s0165-1781(00)00223-7.
8. Gormsen L, Bach FW, Rosenberg R, et al. Differential pain modulation in patients with peripheral neuropathic pain and fibromyalgia. *Scand J Pain* 2012;3(3):116-123; doi: 10.1016/j.sjpain.2012.01.002.
9. Chalaye P, Lafrenaye S, Goffaux P, et al. The role of cardiovascular activity in fibromyalgia and conditioned pain modulation. *Pain* 2014;155(6):1064-1069; doi: 10.1016/j.pain.2013.12.023.
10. Ellingson LD, Stegner AJ, Schwabacher IJ, et al. Catastrophizing Interferes with Cognitive Modulation of Pain in Women with Fibromyalgia. *Pain Med* 2018;19(12):2408-2422; doi: 10.1093/pm/pny008.
11. Lazaridou A, Paschali M, Schreiber K, et al. The association between daily physical exercise and pain among women with fibromyalgia: the moderating role of pain catastrophizing. *Pain Rep* 2020;5(4):e832; doi: 10.1097/PR9.0000000000000832.
12. Christenfeld N. Memory for pain and the delayed effects of distraction. *Health Psychol* 1997;16(4):327-330; doi: 10.1037//0278-6133.16.4.327.
13. McCaul KD, Haugtvedt C. Attention, distraction, and cold-pressor pain. *J Pers Soc Psychol* 1982;43(1):154-162; doi: 10.1037//0022-3514.43.1.154.
14. Kohl A, Rief W, Glombiewski JA. Acceptance, cognitive restructuring, and distraction as coping strategies for acute pain. *J Pain* 2013;14(3):305-315; doi: 10.1016/j.jpain.2012.12.005.
15. Moont R, Pud D, Sprecher E, et al. 'Pain inhibits pain' mechanisms: Is pain modulation simply due to distraction? *Pain* 2010;150(1):113-120; doi: 10.1016/j.pain.2010.04.009.
16. Van Ryckeghem DM, Van Damme S, Eccleston C, et al. The efficacy of attentional distraction and sensory monitoring in chronic pain patients: A meta-analysis. *Clinical psychology review* 2018;59:16-29; doi: 10.1016/j.cpr.2017.10.008.
17. Todd J, van Ryckeghem DML, Sharpe L, et al. Attentional bias to pain-related information: a meta-analysis of dot-probe studies. *Health Psychol Rev* 2018;12(4):419-436; doi: 10.1080/17437199.2018.1521729.
18. Crombez G, Van Ryckeghem DML, Eccleston C, et al. Attentional bias to pain-related information: a meta-analysis. *Pain* 2013;154(4):497-510; doi: 10.1016/j.pain.2012.11.013.
19. Campbell CM, Witmer K, Simango M, et al. Catastrophizing delays the analgesic effect of distraction. *Pain* 2010;149(2):202-207; doi: 10.1016/j.pain.2009.11.012.
20. Pourmand A, Davis S, Marchak A, et al. Virtual Reality as a Clinical Tool for Pain Management. *Curr Pain Headache Rep* 2018;22(8):53; doi: 10.1007/s11916-018-0708-2.

21. Polat M, Kahveci A, Muci B, et al. The Effect of Virtual Reality Exercises on Pain, Functionality, Cardiopulmonary Capacity, and Quality of Life in Fibromyalgia Syndrome: A Randomized Controlled Study. *Games Health J* 2021;10(3):165-173; doi: 10.1089/g4h.2020.0162.
22. Boutron I, Altman DG, Moher D, et al. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Annals of internal medicine* 2017;167(1):40-47; doi: 10.7326/m17-0046.
23. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. *Arthritis Rheum* 1990;33(2):160-172; doi: 10.1002/art.1780330203.
24. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. *Arthritis Care Res (Hoboken)* 2010;62(5):600-610; doi: 10.1002/acr.20140.
25. Vaegter HB, Handberg G, Graven-Nielsen T. Hypoalgesia After Exercise and the Cold Pressor Test is Reduced in Chronic Musculoskeletal Pain Patients With High Pain Sensitivity. *Clin J Pain* 2016;32(1):58-69; doi: 10.1097/AJP.0000000000000223.
26. Mitchell LA, MacDonald RA, Brodie EE. Temperature and the cold pressor test. *J Pain* 2004;5(4):233-237; doi: 10.1016/j.jpain.2004.03.004.
27. Gutierrez-Maldonado J, Gutierrez-Martinez O, Loreto-Quijada D, et al. The use of virtual reality for coping with pain with healthy participants. *Psicothema* 2012;24(4):516-522.
28. Potvin S, Marchand S. Pain facilitation and pain inhibition during conditioned pain modulation in fibromyalgia and in healthy controls. *Pain* 2016;157(8):1704-1710; doi: 10.1097/j.pain.0000000000000573.
29. Miro J, Castarlenas E, de la Vega R, et al. Pain catastrophizing, activity engagement and pain willingness as predictors of the benefits of multidisciplinary cognitive behaviorally-based chronic pain treatment. *J Behav Med* 2018;41(6):827-835; doi: 10.1007/s10865-018-9927-6.
30. Delgado DA, Lambert BS, Boutris N, et al. Validation of Digital Visual Analog Scale Pain Scoring With a Traditional Paper-based Visual Analog Scale in Adults. *J Am Acad Orthop Surg Glob Res Rev* 2018;2(3):e088; doi: 10.5435/JAAOSGlobal-D-17-00088.
31. Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. *Pain* 1986;27(1):117-126.
32. Verhoeven K, Crombez G, Eccleston C, et al. The role of motivation in distracting attention away from pain: an experimental study. *Pain* 2010;149(2):229-234; doi: 10.1016/j.jpain.2010.01.019.
33. Kjogx H, Zachariae R, Pfeiffer-Jensen M, et al. Pain frequency moderates the relationship between pain catastrophizing and pain. *Front Psychol* 2014;5:1421; doi: 10.3389/fpsyg.2014.01421.
34. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: Development and validation. *Psychol Assessment* 1995;7(4):524-532; doi: Doi 10.1037/1040-3590.7.4.524.
35. Toupet M, Ferrary E, Grayeli AB. Visual analog scale to assess vertigo and dizziness after repositioning maneuvers for benign paroxysmal positional vertigo. *J Vestib Res* 2011;21(4):235-241; doi: 10.3233/VES-2011-0420.
36. Witmer BG, Singer MJ. Measuring Presence in Virtual Environments: A Presence Questionnaire. *Presence* 1998;7(3):225-240; doi: 10.1162/105474698565686.
37. Tong X, Gromala D, Gupta D, et al. Usability Comparisons of Head-Mounted vs. Stereoscopic Desktop Displays in a Virtual Reality Environment with Pain Patients. *Stud Health Technol Inform* 2016;220:424-431.
38. Cohen J. *Statistical power analysis for the behavioural sciences*. Erlbaum: Hillsdale, NJ; 1988.
39. Ellis PD. *The Essential Guide to Effect Sizes: Statistical Power, Meta-Analysis, and the Interpretation of Research Results*. Cambridge University Press: Cambridge; 2010.
40. Matheve T, Bogaerts K, Timmermans A. Virtual reality distraction induces hypoalgesia in patients with chronic low back pain: a randomized controlled trial. *J Neuroeng Rehabil* 2020;17(1):55; doi: 10.1186/s12984-020-00688-0.

41. Patel P, Ivanov D, Bhatt S, et al. Low-Cost Virtual Reality Headsets Reduce Perceived Pain in Healthy Adults: A Multicenter Randomized Crossover Trial. *Games Health J* 2020;9(2):129-136; doi: 10.1089/g4h.2019.0052.
42. Jones T, Moore T, Choo J. The Impact of Virtual Reality on Chronic Pain. *PLoS One* 2016;11(12):e0167523; doi: 10.1371/journal.pone.0167523.
43. Wiederhold BK, Gao K, Kong L, et al. Mobile devices as adjunctive pain management tools. *Cyberpsychol Behav Soc Netw* 2014;17(6):385-389; doi: 10.1089/cyber.2014.0202.
44. Rutter CE, Dahlquist LM, Weiss KE. Sustained efficacy of virtual reality distraction. *J Pain* 2009;10(4):391-397; doi: 10.1016/j.jpain.2008.09.016.
45. Shahrbanian S, Ma X, Korner-Bitensky N, et al. Scientific evidence for the effectiveness of virtual reality for pain reduction in adults with acute or chronic pain. *Stud Health Technol Inform* 2009;144:40-43.
46. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. *Clin J Pain* 1997;13(3):189-196; doi: 10.1097/00002508-199709000-00003.
47. Eccleston C, Crombez G. Pain demands attention: a cognitive-affective model of the interruptive function of pain. *Psychol Bull* 1999;125(3):356-366; doi: 10.1037/0033-2909.125.3.356.
48. Oliva V, Gregory R, Brooks J, et al. Central pain modulatory mechanisms of attentional analgesia are preserved in fibromyalgia. *Pain* 2021; doi: 10.1097/j.pain.0000000000002319.
49. Carleton RN, Asmundson GJG, Korol SL, et al. Evaluating the efficacy of an attention modification program for patients with fibromyalgia: a randomized controlled trial. *Pain* 2020;161(3):584-594; doi: 10.1097/j.pain.0000000000001746.
50. Van Damme S, Crombez G, Eccleston C. Disengagement from pain: the role of catastrophic thinking about pain. *Pain* 2004;107(1-2):70-76; doi: 10.1016/j.pain.2003.09.023.
51. Busch AJ, Webber SC, Richards RS, et al. Resistance exercise training for fibromyalgia. *Cochrane Database Syst Rev* 2013;(12):CD010884; doi: 10.1002/14651858.CD010884.
52. Sosa-Reina MD, Nunez-Nagy S, Gallego-Izquierdo T, et al. Effectiveness of Therapeutic Exercise in Fibromyalgia Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *Biomed Res Int* 2017;2017:2356346; doi: 10.1155/2017/2356346.
53. Kaleth AS, Bigatti SM, Slaven JE, et al. Predictors of Physical Activity in Patients With Fibromyalgia: A Path Analysis. *J Clin Rheumatol* 2022;28(1):e203-e209; doi: 10.1097/RHU.0000000000001684.
54. Talbot JD, Duncan GH, Bushnell MC, et al. Diffuse noxious inhibitory controls (DNICs): psychophysical evidence in man for intersegmental suppression of noxious heat perception by cold pressor pain. *Pain* 1987;30(2):221-232; doi: 10.1016/0304-3959(87)91078-5.
55. Eccleston C. The attentional control of pain: methodological and theoretical concerns. *Pain* 1995;63(1):3-10; doi: 10.1016/0304-3959(95)00093-8.
56. Harris G, Rollman GB. The validity of experimental pain measures. *Pain* 1983;17(4):369-376; doi: 10.1016/0304-3959(83)90168-9.

## **FIGURE LEGENDS:**

### **Figure 1 – Study overview**

Study overview showing the cross-over design with the control condition (CC) and a VR-condition (VR-C) during experimentally induced pain (ice water immersion), separated by a 20-minute break.


### **Figure 2 – Pain outcomes**




Cold pain threshold (**a**), pain tolerance (**b**) represented by number of seconds participants kept their foot in the ice water prior to reporting pain (threshold) and removing their foot (tolerance), and pain intensity (**c**) (VAS score (Cm): 0=No pain, 10=Worst imaginable pain) during the two conditions (CC and VR-C) for both groups (Fibromyalgia and pain-free individuals). Data presented as median, Q1, Q3 and IQR. \*Significant within-group difference between conditions (Wilcoxon's test:  $P < 0.05$ ).

**Table 1:** Participant characteristics for the fibromyalgia (n=22) and the control (n=22) group. Data are presented as count (percentage), mean  $\pm$  SD or median and interquartile range (25th percentile and 75th percentile).

| <b>Variable</b>                              | <b>Fibromyalgia patients</b> | <b>Pain-free individuals</b> |
|--|------------------------------|------------------------------|
| Sex (F)                                      | 22 (100)                     | 22 (100)                     |
| Age, years                                   | 47.6 $\pm$ 6.6               | 47.6 $\pm$ 6.6               |
| Right-legged                                 | 17 (77.3)                    | 21 (95.5)                    |
| Resting pain intensity (VAS: 0-10 cm)        | 4.6 [3.4 - 5.4]              | 0.0 [0.0 - 0.2]              |
| Pain intensity before CC                     | 4.4 [3.5 - 5.6]              | 0.0 [0.0 - 0.2]              |
| Pain intensity before VR-C                   | 5.0 [3.4 - 6.5]              | 0.0 [0.0 - 0.0]              |
| Time since fibromyalgia diagnosis            |                              |                              |
| • 0-1 year                                   | 8 (36.4)                     |                              |
| • 2-5 years                                  | 5 (22.7)                     |                              |
| • More than 5 years                          | 9 (40.9)                     |                              |
| Pain Catastrophizing Scale (PCS: 0-52) score | 21.6 $\pm$ 10.4              | 13.2 $\pm$ 9.0               |







**SUPPLEMENTARY FILE 1**

**Table S1** Mean difference (SD) between conditions (Virtual Reality: VR-C; Control Condition: CC) and 95% CI for the primary outcomes (pain-threshold (seconds), tolerance (seconds) and intensity (VAS 0=no pain, 10=maximal imaginable pain))for both groups (Fibromyalgia; Control). For pain threshold and -tolerance a positive value indicated hypoalgesia in the VR-C, whereas for pain intensity a negative value indicated hypoalgesia in the VR-C.

|                     | Fibromyalgia    |              | Control         |              |
|---------------------|-----------------|--------------|-----------------|--------------|
|                     | Mean Difference | 95% CI       | Mean Difference | 95% CI       |
| Pain threshold (s)  | 35.4 (49.2)     | 13.6 to 57.2 | 67.7 (59.2)     | 41.4 to 93.9 |
| Pain tolerance (s)  | 27.3 (32.7)     | 12.8 to 41.8 | 25.0 (54,6)     | 0.8 to 49.3  |
| Pain intensity (cm) | -0.3 (1.8)      | -1.1. to 0.4 | -1.8 (2.3)      | -2.8 to -0.7 |